Hypertension: Do we need to consider the biological clock in drug dosing?

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 3, 2007, Pages 375-379

  Lemmer, Björn ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ISRADIPINE; LACIDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PERINDOPRIL; PROPRANOLOL; QUINAPRIL; TRANDOLAPRIL; TRANSCRIPTION FACTOR CLOCK; VALSARTAN; VERAPAMIL;

BIOLOGICAL RHYTHM; BLOOD PRESSURE MONITORING; CELL FUNCTION; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MARKETING; DRUG USE; EDITORIAL; GENETIC REGULATION; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; META ANALYSIS; NIGHT; SINGLE DRUG DOSE; SUSTAINED RELEASE FORMULATION; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; CIRCADIAN RHYTHM; HUMANS; HYPERTENSION;

EID: 34249340086     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.3.375     Document Type: Editorial

References (32)

1. Cannon CP, McCabe CH, Stone PH et al. Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). Am. J. Cardiol. 79, 253-258 (1997).
2. Glasser SP, Neutel JM, Gana TJ, Albert KS. Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension. Am. J. Hypertens. 16, 51-58 (2003).
3. Sista S, Chi-Keung Lai J, Eradiri O, Albert K. Pharmacokinetics of a novel diltiazem HCL extended-release tablet formulation for evening administration. J. Cin. Pharmacol. 43, 1149-1157 (2003).
4. Sica D, Frishman WH, Manowitz N. Pharmacokinetics of propranolol after single and multiple dosing with sustained released propranolol or propranolol CR (Innopran XL ™), a new chronotherapeutic formulation. Heart Disease 5, 176-181 (2003).
5. Neutel JM, Rotemberg K. Comparison of a chronotherapeutically administered β blocker vs. a traditionally administered β blocker in patients with hypertension. J. Clin. Hypertens. 7, 395-400 (2005).
6. Prisant LM, Devane JG, Butler J. A steady state evaluation of the bioavailability of chronotherapeutic oral drug absorption system verapamil PM after nighttime dosing versus immediate-acting verapamil dosed every eight hours. Am. J. Ther. 7, 345-251 (2000).
7. Prisant LM, Weber M, Black HR. The role of circadian rhythm in cardiovascular function-efficacy of a chronotherapeutic approach to controlling hypertension with Veralan PM (verapamil HCL). Today's Therapeutic Trends 21, 201-213 (2003).
8. Smith DHG, Neutel JM, Weber MA. A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning. Am. J. Hypertens. 14, 14-19 (2001).
9. White W, Mehrotra D, Black HR, Kakouhi DT. Effects of controlled-onset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers). Am. J. Cardiol. 80, 469-474 (1997).
10. White WB, Anders RJ, MacInyre JM, Black HR, Sica DA. Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Am. J. Cardiol. 76, 375-380 (1995).
11. White WB, Black HR, Weber M, Elliott WJ, Bryzinski B, Fakouhi TD. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and heart rate-blood pressure product. Am. J. Cardiol. 81, 424-431 (1998).
12. Cutler NR, Anders RJ, Sanford S et al. Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. Am. J. Cardiol. 75, 1102-1106 (1995).
13. Gupta SK, Yih BM, Atkinson L, Longstreth J. The effect of food, time of dosing and body composition on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil. J. Clin. Pharmacol. 35, 1083-1093 (1995).
14. Mengden T, Binswanger B, Gruene S, Spühler T, Weisser B, Vetter W. Dynamics of drug compliance and 24-hour blood pressure control of once daily morning vs evening amlodipine. J. Hypertens. 10(Suppl. 4), S136(P103) (1992).
15. Nold G, Strobel G, Lemmer B. Morning versus evening amlodipine: effect on circadian blood pressure profile in essential hypertensive patients. Blood Press. Monit. 3, 17-25 (1998).
16. Fogari R, Malacco E, Tettamanti F, Gnemmi AE, Milani M. Evening vs morning isradipine sustained release in essential hypertension - a double-blind study with 24-h ambulatory monitoring. Br. J. Clin. Pharmacol. 35, 51-54 (1993).
17. van Montfrans GA, Schelling A, Buurke EJ, Schut N, Houben JJ. Dosing time of lacidipine and the circadian blood pressure curve: the MOTIME study. J. Hypertens. 16(Suppl. 9), S15-S19 (1998).
18. Greminger P, Suter PM, Holm D, Kobelt R, Vetter W. Morning versus evening administration of nifedipine gastrointestinal therapeutic system in the management of essential hypertension. Clin. Investig. 72, 864-869 (1994).
19. White WB, Mansoor GA, Pickering TG et al. Differential effects of morning and evening dosing of nisoldipine ER on circadian blood pressure and heart rate. Am. J. Hypertens. 12, 806-814 (1999).
20. Meilhac B, Mallion JM, Carre A et al. Antihypertensive effect and tolerance of nitrendipine administered either in the morning or in the evening of office and ambulatory blood pressure. Therapie 47, 205-210 (1992).
21. Umeda T, Naomi S, Iwaoka T et al. Timing for administration of an antihypertensive drug in the treatment of essential hypertension. Hypertension 23(Suppl. 1), I211-I214 (1994).
22. Lemmer B, Luders S, Nold G, Schrader J, Manfredini R, Portaluppi F. Normalisation of non-dipping blood pressure profile by amlodipine after single morning or evening dosing. Am. J. Hypertens. 15, 109A (2002).
23. Portaluppi F, Vergnani L, Manfredini R, degli Uberti EC, Fersini C. Time-dependent effect of isradipine on the nocturnal hypertension of chronic renal failure. Am. J. Hypertens. 8, 719-726 (1995).
24. Lemmer B, Nold G, Behne S, Kaiser R. Chronopharmacokinetics and cardiovascular effects of nifedipine. Chronobiol. Int. 8, 485-494 (1991).
25. Lemmer B. The importance of circadian rhythms on drug response in hypertension and coronary heart disease - from mice and man. Pharmacol. Ther. 111, 629-651 (2006).
26. Palatini P, Mos L, Motolese M et al. Effect of evening versus morning benazepril on 24-hour blood pressure - a comparative study with continuous intraarterial monitoring. Int. J. Clin. Pharmacol. Ther. Toxicol. 31, 295-300 (1993).
27. Witte K, Weisser K, Neubeck M et al. Cardiovascular effects, pharmacokinetics, and converting enzyme inhibition of enalapril after morning versus evening administration. Clin. Pharmacol. Ther. 54, 177-186 (1993).
28. Morgan T, Anderson A, Jones E. The effect on 24 h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night. J. Hypertens. 15, 205-211 (1997).
29. Palatini P, Racioppa A, Raule G, Zaninotto M, Penzo M, Pessina AC. Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril. Clin. Pharmacol. Ther. 52, 378-383 (1992).
30. Myburgh DP, Verho M, Botes JH, Erasmus TP, Luus HG. 24-hour blood pressure control with ramipril: comparison of once-daily morning and evening administration. Curr. Ther. Res. Clin. Exp. 56, 1298-1306 (1995).
31. Koroda T, Kario K, Hoshide S et al. Effects of bedtime vs. morning administration of the long-acting lipophilic angiotensin-converting enzyme inhibitor trandolapril on morning blood pressure in hypertensive patients. Hypertens. Res. 27, 15-20 (2004).
32. Hermida RC, Calvo C, Ayala DE et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 42, 283-290 (2003).